Copied to clipboard!

I-BCT-1 (Improved Breast Cancer Therapy) - WXS

A prospective, randomized neoadjuvant study that evaluates DNA-based biomarkers to identify breast cancer patients most likely to benefit from carboplatin (Cb). While Cb improves outcomes in triple-negative breast cancer (TNBC), responses vary, and its role in aggressive hormone receptor–positive breast cancer (HR+BC) remains uncertain. Patients (N = 187) with early, high-risk, HER2-negative cT2-4 tumors received 12 weekly paclitaxel with or without Cb, followed by four cycles of epirubicin and cyclophosphamide. Whole Exome Sequencing data for normal-tumor pairs from the same subjects is available in the matching study titled I-BCT-1 (Improved Breast Cancer Therapy) - WES

Type: Transcriptome Analysis
Archive: Federated EGA Norway Federated EGA Node

1 Dataset

Click on a Dataset ID in the table below to learn more, and to find out who to contact about access to these data

Dataset ID	Description	Technology	Samples
EGAD50000003092	Study Purpose and Design This RNA-seq dataset is derived from the same prospective, randomized neoadjuvant breast cancer trial (IBCT-1) and complements the WXS analysis. RNA sequencing was performed at basline to characterize transcriptomic biomarkers associated with carboplatin response prediction. The cohort includes 187 patients breast cancer tumors across multiple subtypes. Sample Composition - Total samples: 187 (tumor tissue only) Tumor samples: 187 - Sample type: RNA from primary tumor tissue biopsies Technical Specifications - Sequencing platform: Illumina HiSeq4000 - Read type: Paired-end - Read length: 2 × 76 bp - Library preparation: KAPA RNA HyperPrep kit with Twist Bioscience Human Comprehensive Exome Plus RefSeq v1 hybrid selection - RNA input: 100 ng per sample - Sequencing depth: Mean of 35 million read pairs per sample	Illumina HiSeq 4000	187